PTGX FY 2023 Earnings — Protagonist Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTGXProtagonist Therapeutics, Inc.

$6B

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$60M+125.7% YoY

Gross Profit

$60M100.0% margin

Operating Income

-$94M-156.1% margin

Net Income

-$79M-131.6% margin

EPS (Diluted)

$-1.39

Cash Flow

Operating Cash Flow

-$70M

Free Cash Flow

-$71M

Stock-Based Comp.

$29M

Balance Sheet

Total Assets

$358M

Total Liabilities

$21M

Stockholders' Equity

$337M

Cash & Equivalents

$187M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$60M	$27M	+125.7%
Gross Profit	$60M	$27M	+125.7%
Operating Income	-$94M	-$131M	+28.7%
Net Income	-$79M	-$127M	+38.0%